FDA grants AT-007 paediatric rare disease designation and orphan designation for treatment of PMM2-CDG

24 September 2020 - Applied Therapeutics announced today that the U.S. FDA has granted AT-007 both paediatric rare disease designation and ...

Read more →

FDA accepts supplemental new drug application for Pfizer’s Xalkori (crizotinib) for the treatment of paediatric ALK positive anaplastic large cell lymphoma

23 September 2020 - If approved, Xalkori would be the first biomarker driven therapy for paediatric ALK positive anaplastic large cell ...

Read more →

Crinetics Pharmaceuticals receives rare paediatric disease designation from FDA for CRN04777 for the treatment of congenital hyperinsulinism

21 September 2020 - Crinetics Pharmaceuticals today announced that the U.S. Food and Drug FDA has granted rare paediatric disease designation ...

Read more →

FDA granted paediatric disease designation for OXi-4503

16 September 2020 - Treatment of acute myeloid leukaemia due to genetic mutations that disproportionately affect paediatric patients. ...

Read more →

Ziopharm Oncology granted rare paediatric disease designation for controlled IL-12 for the treatment of DIPG

14 September 2020 -  -- Ziopharm Oncology today announced that the U.S. FDA has granted rare paediatric disease designation to ...

Read more →

Clarity Pharmaceuticals announces the US FDA grants rare paediatric disease designation to 64 Cu sartate, a diagnostic for the clinical management of neuroblastoma

9 September 2020 - Clarity Pharmaceuticals is pleased to announce that the U.S. FDA has granted rare paediatric disease designation to ...

Read more →

Editas Medicine receives rare paediatric disease designation for EDIT-301 for the treatment of sickle cell disease

24 August 2020 - Editas Medicine today announced that the U.S. FDA has granted rare paediatric disease designation for EDIT-301, an ...

Read more →

BioMarin submits new drug application to U.S. FDA for vosoritide to treat children with achondroplasia

20 August 2020 - Potential first treatment for achondroplasia in the United States. ...

Read more →

FDA approves first paediatric indication for Xeomin (incobotulinumtoxinA) for the treatment of upper limb spasticity, excluding spasticity caused by cerebral palsy

19 August 2020 - Xeomin was also granted FDA priority review for an application for paediatric sialorrhea, reinforcing Merz Therapeutics’ commitment ...

Read more →

U.S. FDA grants rare paediatric disease designation to AmideBio’s glucagon analog for the treatment of congenital hyperinsulinism

20 August 2020 - AmideBio announced today that the US FDA Offices of Pediatric Therapeutics and Orphan Products Development granted a ...

Read more →

Polaryx Therapeutics receives FDA fast track designation to PLX-200 for the treatment of patients with juvenile neuronal ceroid lipofuscinosis

20 August 2020 - Polaryx Therapeutics announced today that the U.S. FDA has granted fast track designation to PLX-200 for ...

Read more →

Theranexus and BBDF obtain orphan drug designation and rare paediatric disease designation from the FDA for BBDF-101 for Batten disease

11 August 2020 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation ...

Read more →

U.S. Food and Drug Administration approves Lampit (nifurtimox) for the treatment of Chagas disease in children

7 August 2020 - Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 ...

Read more →

US FDA grants rare paediatric disease designation to paxalisib for DIPG

7 August 2020 - Kazia Therapeutics is pleased to announce that the United States FDA has awarded rare paediatric disease designation ...

Read more →

Cerecor receives rare paediatric disease designation for CERC-006 in lymphatic malformations

4 August 2020 - Cerecor today announced that the U.S. FDA granted rare paediatric disease designation to CERC-006, a dual inhibitor ...

Read more →